Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Illumina Launches Infinium® HumanCore Arrays

Published: Wednesday, February 06, 2013
Last Updated: Wednesday, February 06, 2013
Bookmark and Share
Ideal screening array for biobanks, genome centers, and core labs.

Illumina, Inc. has launched the Infinium HumanCore BeadChip family of products. With content developed in collaboration with several leading research institutions, the customizable Infinium HumanCore and Infinium HumanCoreExome BeadChips support cost-effective, large-scale genotyping and screening studies such as those performed by biobanks, genome centers, and core labs.

Based on Illumina's proven Infinium assay, the BeadChips enable genotyping of markers found across diverse populations, making them ideal for researchers engaged in population genetics studies around the world.

"These powerful, cost-effective arrays were specifically designed to make genotyping accessible to a wider range of researchers and laboratories," said Christian Henry, Senior Vice President and General Manager, Genomic Solutions at Illumina.

Henry continued, "Infinium HumanCore BeadChips combine affordability and high-throughput sample processing using the industry's best multi-sample array. The high-quality, genome-wide information they deliver can be used for a variety of downstream applications."

Both customizable arrays include content important for disease research, including association studies and copy number variant discovery and analysis.

The Infinium HumanCore BeadChip features highly-informative, genome-wide tag SNPs and additional high value markers such as indels and updated exome-focused content.

The higher density Infinium HumanCoreExome BeadChip provides that same valuable core content, along with informative markers from the popular HumanExome BeadChip.

With array scanning performed using Illumina's HiScan® or iScan® systems, these multisample BeadChips are equally useful for efficiently and cost-effectively genotyping large populations, screening and quality control of samples prior to sequencing, or generating baseline genomic datasets of general sample cohorts.

"It's clear that large sample sizes are key to furthering progress in human genetics, and Illumina has been a partner to develop an array that will enable these studies," said Mark McCarthy, Robert Turner Professor of Diabetes at the University of Oxford and an array design team member.

McCarthy continued, "The HumanCoreExome BeadChip will be particularly valuable for research utilizing large sample studies. The combination of genome-wide tag SNPs and an enhanced set of exome markers, with the potential to add substantial custom content, will drive the next wave of association discovery for SNPs and CNVs."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Forms New Company
GRAIL to enable early cancer detection via blood-based screening.
Tuesday, January 12, 2016
Verinata Health's verifi® Prenatal Test Available through the California Prenatal Screening Program
verifi® prenatal test will be available to pregnant women in California.
Tuesday, November 05, 2013
Illumina Acquires Advanced Liquid Logic
Acquisition a key component in the development of complete sample-to-answer solutions for next-generation sequencing.
Wednesday, July 24, 2013
Caris Life Sciences Selects Illumina’s MiSeq® System
Collaboration enhances breadth and depth of therapeutic information to help oncologists better personalize cancer treatment.
Friday, November 09, 2012
BGI Purchases 128 Illumina HiSeq™ 2000 Sequencing Systems
Acquisition puts Beijing Genomics Institute on path to become world's largest sequencing facility.
Thursday, January 14, 2010
Expression Analysis Purchases its First Illumina Genome Analyzer
Illumina's Genome Analyzer sequencing technology will support EA's new plant and animal genomic services.
Friday, January 09, 2009
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos